| Literature DB >> 35109907 |
Yifei Gu1,2, Yi Sun1,2, Sohaib Shujaat1,2, Annabel Braem3, Constantinus Politis1,2, Reinhilde Jacobs4,5,6.
Abstract
BACKGROUND: Titanium and its alloys have been widely employed for bone tissue repair and implant manufacturing. The rapid development of three-dimensional (3D) printing technology has allowed fabrication of porous titanium scaffolds with controllable microstructures, which is considered to be an effective method for promoting rapid bone formation and decreasing bone absorption. The purpose of this systematic review was to evaluate the osteogenic potential of 3D-printed porous Ti6Al4V (Ti64) scaffold for repairing long bone defects in animal models and to investigate the influential factors that might affect its osteogenic capacity.Entities:
Keywords: 3D printing; Animal study; Bone tissue engineering; Ti6Al4V; Titanium alloy
Mesh:
Substances:
Year: 2022 PMID: 35109907 PMCID: PMC8812248 DOI: 10.1186/s13018-022-02960-6
Source DB: PubMed Journal: J Orthop Surg Res ISSN: 1749-799X Impact factor: 2.359
Fig. 1Scope of the systematic review
Inclusion and exclusion criteria used in this study
| Inclusion criteria | Exclusion criteria |
|---|---|
| All in vivo studies which reported on the application of Ti64 scaffold for long bone defect repair | 1. Non-English papers |
| 2. Descriptive studies, in vitro studies, and clinical trials | |
| 3. Studies that used materials other than Ti6Al4V | |
| 4. Partially porous Ti64 implant or Ti64 implant with only a textured surface layer | |
| 5. Animal models with comorbidities (hypertension, diabetes, osteoporosis, etc.) | |
| 6. Not a long bone defect (defect in cranial bone, jaw bone, etc.) |
Fig. 2Screening flow diagram based on the PRISMA guidelines
Fig. 3Relationship between the year of publication and number of included articles
Fig. 4Results of SYRCLE's risk of bias analysis
Fig. 5Results of CAMARADES list of methodological quality assessment
List of Ti64 scaffolds and animal study designs
| Author, date | Fabrication method | Scaffold shape and size ( | Strut size (µm) | Pore size (µm) | Porosity (%) | Unit cell | Modifications to improve biocompatibility | Animal model | Bone defect | Implantation time (weeks) |
|---|---|---|---|---|---|---|---|---|---|---|
| Arabnejad et al. 2016 [ | SLM | C(5 * 10) | 200–400 | 438–772 | 56–70 | Tetrahedron Octahedron | / | Dog | Femur | 4 and 8 |
| Bandyopadhyay et al. 2019 [ | SLM | C(3 * 5) | / | 60–700 | 25 | / | Anodization treatment | Rat | F-epi | 12 |
| Chen et al. 2019 [ | SLM | C(6 * 6) | 300 | 600 | 70 | Sphere | / | Dog | Tibia | 4 and 12 |
| Chen et al. 2020 [ | SLM | C(3 * 4) | / | 500–700 | 60–70 | Octahedron | / | Rat | F-epi | 4 and 12 |
| Crovace et al. 2020 [ | EBM | C(12 * 400) | / | 3600 | 90 | Gyroid | / | Sheep | Tibia(s) | 48 |
| Fan et al. 2020 [ | EBM | C(5 * 13) | 382–383 | 659–663 | 70–71 | / | Barium titanate coating | Rabbit | Radius(s) | 6 and 12 |
| Gilev et al. 2019 [ | SLM | Cubic | / | / | / | / | / | Rabbit | Tibia | 1,2,6,12 and 48 |
| Guo et al. 2020 [ | SLM | C(5 * 10) | / | 340–360 | 70–75 | / | Titanium copper/titanium copper nitride multilayer coating | Rabbit | F-epi | 4, 8 and 12 |
| Guo et al. 2018 [ | SLM | C(5 * 10) | / | 316 | 74 | Cubic | / | Rabbit | F-epi | 4, 8 and 12 |
| Han et al. 2016 [ | EBM | C(5 * 5) | 400 | 600–800 | 55–67 | Cubic | Anodization treatment and strontium incorporation | Rabbit | F-epi | 4 and 12 |
| Hara et al. 2016 [ | EBM | C(5 * 12) | / | 501–933 | 65–70 | Diamond | / | Rabbit | Femur | 4 and 12 |
| Huang et al. 2017 [ | EBM | C(10 * 20) | 238 | 514 | 69 | Diamond | HA coating | Goat | F-epi | 8 and 16 |
| Kelly et al. 2021 [ | SLM | C(4.5 * 8) | / | 739–1076 | 70 | TPMS-based cell | / | Rat | Femur(s) | 12 |
| Koolen et al. 2020 [ | SLS | C(5 * 6) | 211 | 244 | 79 | Rhombic dodecahedron | AlAcH treatment | Rat | Femur(s) | 11 |
| Li et al. 2019 [ | SLM | C(5 * 6) | / | 400 | 45 | Cubic | Polydopamine coating | Rabbit | F-epi | 5 |
| Li et al. 2019 [ | SLM | C(8 * 10) | / | 100–700 | 50 | TPMS-based cell | / | Pig | Tibia | 5 |
| Li et al. 2016 [ | EBM | C(10 * 30) | 200 | 315 | 34 | Diamond | / | Goat | Metatarsus(s) | 12, 24 and 48 |
| Li et al. 2015 [ | EBM | C(5 * 10) | / | 710 | 68 | / | Polydopamine-assisted hydroxyapatite coating | Rabbit | F-epi | 4 and 12 |
| Liu et al. 2016 [ | EBM | C(5 * 16) | 400 | 640 | 76 | / | Addition of simvastatin and hydrogel | Rabbit | Tibia | 4 and 8 |
| Liu et al. 2020 [ | SLM | C(10 * 10) | / | 600 | 65 | / | / | Rabbit | F-epi | 4, 6, 8, 10 and 12 |
| Luan et al. 2019 [ | EBM | C(5 * 4) | / | 334–402 | 55–78 | / | / | Rabbit | Femur | 12 |
| Lv et al. 2015 [ | EBM | C(5 * 6) | / | 640 | / | Hexagonal | Addition of bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor and fibringel | Rabbit | F-epi | 4 |
| Lyu et al. 2020 [ | / | C(2 * 5) | 320 | 650 | 70 | / | / | Rabbit | F-epi | 12 |
| Ma et al. 2018 [ | SLM | C(5 * 6) | / | 400 | 76 | / | Addition of mineralized collagen | Rabbit | Radius(s) | 4 and 12 |
| Ma et al. 2021 [ | SLM | C(15 * 20) | / | 400 | 76 | / | Addition of gelatin methacrylate | Rabbit | Radius(s) | 4 and 12 |
| Mumith et al. 2020 [ | SLS | C(8 * 14.5) | 300–750 | 700–1500 | 70–75 | / | HA coating, silicon-substituted or strontium-substituted HA coating | Sheep | F-epi | 6 |
| Palmquist et al. 2017 [ | EBM | C(5.2 * 5) | 350 | 550 | 70 | Diamond | / | Sheep | Femur and tibia | 24 |
| Palmquist et al. 2013 [ | EBM | C(5.2 * 7) | 500–1000 | 500–700 | 65–70 | / | / | Sheep | F-epi | 26 |
| Ragone et al. 2020 [ | SLM | C(6.2 * 11) | 200 | 450–1200 | 75–90 | Irregular-shaped | / | Sheep | Femur and tibia | 6, 10 and 14 |
| Ran et al. 2018 [ | SLM | C(4 * 13) | 300–400 | 401–801 | / | Circle | / | Rabbit | F-epi | 4 and 12 |
| Shah et al. 2016 [ | EBM | C(5.2 * 7) | 583 | / | 63 | / | / | Sheep | F-epi | 24 |
| Shah et al. 2016 [ | EBM | C(5.2 * 5) | 341 | 470–545 | 70 | Diamond | / | Sheep | F-epi | 26 |
| Song et al. 2019 [ | SLM | C(3 * 6) | 200–400 | / | 65–86 | Diamond | HA coating | Rabbit | Femur | 12 and 24 |
| Tanzer et al. 2019 [ | SLM | C(5.2 * 10) | / | 450 | 50–65 | Irregular-shaped | HA coating | Dog | Femur | / |
| Tsai et al. 2019 [ | SLM | C(6.5 * 10) | / | 350 | / | Cubic | Magnesium–calcium silicate and chitosan coating | Rabbit | Femur | 6 |
| van der Stok et al. 2015 [ | SLM | Femur-shape | 165 | 577 | 85 | Rhombic dodecahedron | AlAcH surface treatment and addition of BMP-2 and fibrin gel | Rat | Femur(s) | 12 |
| van der Stok et al. 2015 [ | SLM | Femur-shape | 120 | 500 | 88 | Rhombic dodecahedron | AlAcH surface treatment and osteostatin coating | Rat | Femur(s) | 12 |
| van der Stok et al. 2013 [ | SLM | Femur-shape | 120–230 | 490 | 68–88 | Rhombic dodecahedron | AlAcH treatment | Rat | Femur(s) | 4,8 and 12 |
| Wang et al. 2018 [ | SLM | C(4.8 * 8) | 410–449 | 427–458 | 61–66 | Diamond Tetrahedron | / | Rabbit | Femur | 4 and 8 |
| Wang et al. 2018 [ | / | C(8 * 10) | / | 200 | / | / | Strontium ion incorporated zeolite coating | Rabbit | F-epi | 4 |
| Xiu et al. 2017 [ | EBM | C(6 * 5) | 400 | 640 | 73 | Rhombic dodecahedron | Hybrid micro-arc oxidation and hydrothermal treatment | Rabbit | F-epi | 8 |
| Xiu et al. 2017 [ | EBM | C(6 * 5) | 400 | 640 | 73 | Rhombic dodecahedron | Hybrid micro-arc oxidation | Rabbit | F-epi | 8 |
| Yavari et al. 2014 [ | SLM | Femur-shape | 160–180 | 577–596 | 85–89 | Rhombic dodecahedron | Acid–alkali treatment, AlAcH treatment and anodizing-heat treatment | Rat | Femur(s) | 4, 8 and 12 |
| Yu et al. 2020 [ | SLM | Cone-shape | 200 | 650 | 90 | Rhombic dodecahedron | / | Rabbit | Femur | 4 and 8 |
| Zhang et al. 2021 [ | SLM | C(5 * 10) | 300 | / | 68 | Diamond | Bioactive glass and mesoporous bioactive glass coating | Rabbit | F-epi | 6 and 9 |
| Zhong et al. 2020 [ | SLM | C(6 * 10) | / | / | / | / | / | Rabbit | F-epi | 6 and 12 |
*C: cylinder; HA: hydroxyapatite; AlAcH: alkali-acid-heat; F-epi: femoral epiphysis; s: segmental bone defect; wk: weeks; m: months
*Data are all average values, and parameters were reserved for integers
*If multiple Ti64 scaffold design parameters have been applied in a single article, the parameters are expressed in ranges
Fig. 6Schematic workflow of a typical animal experiment (Li et al. [41])
Summary of reported BA/TA for pristine Ti64 scaffolds in the reviewed studies
| Author, date | Animal and bone defect | Group | BA/TA (%) | |||
|---|---|---|---|---|---|---|
| 4–6 weeks | 8–10 weeks | 12–14 weeks | 24–26 weeks | |||
| Arabnejad et al. 2016 [ | Beagle dog, femur | Tetrahedron cell | 28.6 ± 11.6 | 41.3 ± 4.3 | / | / |
| Octet truss cell | 35.5 ± 1.9 | 56.9 ± 4. | ||||
| Chen et al. 2019 [ | Beagle dog, tibia | / | 11.9 ± 2.2 | / | 15.9 ± 4.9 | / |
| Guo et al. 2020 [ | Rabbit, f-epi | / | 11.6 ± 1.9 | 12.2 ± 2.0 | 24.1 ± 3.0 | / |
| Guo et al. 2018 [ | Rabbit, f-epi | / | 13.2 ± 2.7 | 35.6 ± 2.7 | 55.9 ± 2.0 | / |
| Han et al. 2016 [ | Rabbit, f-epi | Pore size 600 μm | 2.3 ± 0.4 | / | 3.5 ± 0.5 | / |
| Pore size 800 μm | 1.5 ± 0.1 | / | 2.4 ± 0.4 | / | ||
| Hara et al. 2016 [ | Rabbit, femur | Pore size 500 μm | 34.9 ± 6.8 | / | 50.1 ± 8.3 | / |
| Pore size 640 μm | 37.0 ± 5.0 | / | 50.9 ± 6.7 | / | ||
| Pore size 800 μm | 27.2 ± 7.2 | / | 51.6 ± 6.4 | / | ||
| Pore size 1000 μm | 34.7 ± 8.4 | / | 35.1 ± 2.7 | / | ||
| Li et al. 2015 [ | Rabbit, f-epi | / | 5.8 ± 2.2 | / | 12.2 ± 2.2 | / |
| Lv et al. 2015 [ | Rabbit, f-epi | / | 7.8 ± 2.8 | / | / | / |
| Palmquist et al. 2017 [ | Sheep, femur and tibia | Scaffold in femur | / | / | / | Central: 26.5 ± 9.2 Peripheral: 57.2 ± 10.9 |
| Scaffold in tibia | / | / | / | Central: 45.6 ± 19.5 Peripheral: 8.0 ± 10.4 | ||
| Palmquist et al. 2017 [ | Sheep, f-epi | / | / | / | / | 44.7 ± 4.4 |
| Ragone et al. 2020 [ | Sheep, femur and tibia | / | Cortical: 75.0 ± 13.5 Cancellous: 27.0 ± 15.0 | Cortical: 82.0 ± 5.0 Cancellous: 36.0 ± 10.5 | Cortical: 82.0 ± 9.0 Cancellous: 51.0 ± 14.0 | / |
| Shah et al. 2016 [ | Sheep, f-epi | / | / | / | / | Central: 32.9 ± 4.8 Peripheral: 60.0 ± 4.6 |
| Song et al. 2019 [ | Rabbit, femur | / | / | / | 6.8 ± 2.9 | 35.6 ± 5.3 |
| Tanzer et al. 2019 [ | Beagle dog, femur | / | 41.5 ± 8.2 | / | 64.4 ± 2.8 | / |
| Tsai et al. 2019 [ | Rabbit, femur | / | 2.5 ± 0.8 | / | / | / |
| Wang et al. 2018 [ | Rabbit, femur | Diamond cell (r) | 34.0 ± 5.9 | 36.3 ± 1.0 | / | / |
| Diamond cell (ir) | 33.7 ± 5.0 | 36.8 ± 2.3 | / | / | ||
| Diamond cell (g) | 30.2 ± 3.3 | 32.3 ± 4.9 | / | / | ||
| Tetrahedron cell | 20.5 ± 3.0 | 24.3 ± 1.9 | / | / | ||
| Xiu et al. 2017 [ | Rabbit, f-epi | / | / | 8.2 ± 2.3 | / | / |
| Xiu et al. 2017 [ | Rabbit, f-epi | / | / | 10.8 ± 3.4 | / | / |
| Yu et al. 2020 [ | Rabbit, femur | / | 46.3 ± 13.7 | 59.3 ± 8.1 | / | / |
*F-epi: femoral epiphysis; r: regularly distributed pores; ir: irregularly distributed pores; g: gradient distributed pores
*The data are all represented as means ± standard deviations, and reserved for one decimal point
Summary of reported BV/TV for pristine Ti64 scaffolds in the reviewed studies
| Author, date | Animal and bone defect | Group | BV/TV (%) | |||
|---|---|---|---|---|---|---|
| 4–6 weeks | 8–10 weeks | 12 weeks | 16 weeks | |||
| Chen et al. 2020 [ | Rat, f-epi | Porosity 60%, pore size 500 μm | / | / | 23.4 ± 1.6 | / |
| Porosity 60%, pore size 600 μm | / | / | 21.0 ± 2.1 | / | ||
| Porosity 60%, pore size 700 μm | / | / | 12.8 ± 2.1 | / | ||
| Porosity 70%, pore size 500 μm | / | / | 23.2 ± 1.8 | / | ||
| Porosity 70%, pore size 600 μm | / | / | 22.3 ± 1.0 | / | ||
| Porosity 70%, pore size 700 μm | / | / | 18.3 ± 1.4 | / | ||
| Guo et al. 2020 [ | Rabbit, f-epi | / | 11.6 ± 1.8 | 17.1 ± 1.6 | 25.5 ± 2.6 | / |
| Han et al. 2016 [ | Rabbit, f-epi | Pore size 600 μm | 8.4 ± 1.3 | / | 16.2 ± 3.6 | / |
| Pore size 800 μm | 4.3 ± 1.0 | / | 8.6 ± 2.7 | / | ||
| Huang et al. 2017 [ | Goat, f-epi | / | / | 5.1 ± 1.8 | / | 6.3 ± 2.2 |
| Li et al. 2019 [ | Rabbit, f-epi | / | 13.7 | / | / | / |
| Li et al. 2019 [ | Pig, tibia | Pore size 300-500 μm | 12.7 ± 3.6 | / | / | / |
| Pore size 200-600 μm | 12.0 ± 3.6 | / | / | / | ||
| Pore size 100-700 μm | 12.8 ± 3.9 | / | / | / | ||
| Li et al. 2015 [ | Rabbit, f-epi | / | 5.9 ± 2.2 | / | 11.0 ± 2.6 | / |
| Liu et al. 2016 [ | Rabbit, tibia | / | 26.7 ± 1.0 | 28.9 ± 1.4 | / | / |
| Luan et al. 2019 [ | Rabbit, femur | Porosity 55%, pore size 334 μm | / | / | 21.4 ± 2.2 | / |
| Porosity 65%, pore size 383 μm | / | / | 24.6 ± 2.0 | / | ||
| Porosity 78%, pore size 400 μm | / | / | 26.7 ± 0.9 | / | ||
| Lyu et al. 2020 [ | Rabbit, f-epi | / | / | / | 34.0 ± 6.0 | / |
| Wang et al. 2018 [ | Rabbit, f-epi | / | 6.0 ± 0.2 | / | / | / |
| Yu et al. 2020 [ | Rabbit, femur | / | 27.3 ± 8.4 | 29.8 ± 2.2 | / | / |
| Zhang et al. 2021 [ | Rabbit, f-epi | / | 13.4 ± 1.0 | 16.6 ± 2.18 | / | / |
| Zhong et al. 2020 [ | Rabbit, f-epi | / | 13.9 ± 1.5 | / | 16.0 ± 1.3 | / |
*F-epi: femoral epiphysis
*The data are all represented as means ± standard deviations, and reserved for one decimal point